Reduced Coenzyme Q10 Crystal Form With Low Oxidation Residue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing reduced coenzyme Q10 crystals face challenges such as oxidation during manufacturing, leading to reduced purity and stability, and the use of solvents like aliphatic hydrocarbons results in solvent residues, making it difficult to achieve high-purity and stable crystal forms.
Innovation Solution
A method involving crystallization of reduced coenzyme Q10 in the presence of cyclic ether solvents, fluorine-containing alcohol solvents, and organic bases under controlled conditions to produce a novel crystal form with enhanced stability and purity, characterized by specific X-ray diffraction and infrared absorption peaks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional reducing agents and aliphatic hydrocarbon solvents are used to produce reduced coenzyme Q10 crystals, then the manufacturing process is simple, but oxidation occurs during manufacturing leading to reduced purity and stability
Solution Approach 1:
The patent employs an inert atmosphere (nitrogen or carbon dioxide) during the crystallization process to prevent oxidation of reduced coenzyme Q10. The reaction vessel is filled with inert gas before and during crystallization, creating an oxygen-free environment that maintains product stability and purity while allowing the manufacturing process to proceed with conventional reducing agents and solvents.
Solution Approach 2:
The patent introduces specific solvent systems (cyclic ether solvents combined with fluorine-containing alcohol solvents) as intermediaries that facilitate crystallization while protecting against oxidation. These solvent combinations create a controlled environment that enables high-purity crystal formation without direct exposure to oxygen, resolving the contradiction between manufacturing simplicity and product stability.
2Manufacturing precision
If aliphatic hydrocarbon solvents are used for crystallization, then the crystallization process is effective, but solvent residues remain making it difficult to achieve high-purity crystal forms
Solution Approach 1:
The patent changes the chemical parameters of the solvent system by replacing aliphatic hydrocarbons with cyclic ether solvents combined with fluorine-containing alcohol solvents. This parameter change results in solvents that either evaporate completely or can be more effectively removed, achieving high-purity crystal forms without persistent solvent residues while maintaining effective crystallization.
Solution Approach 2:
The patent employs solvent systems that can be easily discarded or decomposed. The cyclic ether and fluorine-containing alcohol solvents are selected for their ability to be completely evaporated or degraded, leaving no harmful residues. This approach treats the solvent as a temporary, disposable medium that facilitates crystallization but does not persist in the final product.
3Stability of the object's composition
If reduced coenzyme Q10 is stored or processed, then it remains in reduced form during fermentation, but it is gradually oxidized to oxidized coenzyme Q10 during extraction and storage
Solution Approach 1:
The patent maintains an inert atmosphere throughout the entire process from fermentation to extraction and storage. By filling the reaction vessel with nitrogen or carbon dioxide before extraction and maintaining this atmosphere during filtering, drying, and storage, the reduced coenzyme Q10 is protected from oxidation at all stages, preserving its reduced form stability.
Solution Approach 2:
The patent takes preliminary protective action by establishing an inert atmosphere before any oxidation-prone operations begin. The inert gas is introduced before extraction, filtering, and storage, preventing oxidation from occurring in the first place rather than addressing it after it begins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crystal form exhibits improved stability against oxidation, higher water solubility, and lower solvent residues, maintaining high purity and thermal stability, with a melting point of 52±2°C, and retention rates of 80% or more after storage.
Implementation Method 1
The novel crystal form exhibits improved stability against oxidation, higher water solubility, and lower solvent residues, maintaining high purity and thermal stability, with a melting point of 52±2°C
Implementation Method 2
characterized by specific X-ray diffraction and infrared absorption peaks
Implementation Method 3
characterized by specific X-ray diffraction and infrared absorption peaks
Implementation Method 4
characterized by specific X-ray diffraction and infrared absorption peaks
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention provides a reduced coenzyme Q10 crystal which, when measured by means of differential scanning calorimetry at a heating rate of 10 k/min, exhibits an endothermic peak at 52±2°C. Compared with the prior art, the crystal form of reduced coenzyme Q10 provided by the present invention is more stable than reduced coenzyme Q10 crystals reported in the literature, and other physical properties, including water solubility and residual solvents, are also superior; in addition, the crystal form provided by the present invention also overcomes the disadvantages of previously known reduced coenzyme Q10, which is very easily oxidized and has limitations in use; furthermore, the reduced coenzyme Q10 crystal and a crystalline solid containing the crystal provided by the present invention not only have excellent physical properties in terms of stability, but also stand out in terms of high purity and low solvent residue.